Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage i or II Chronic Kidney Disease

Clinical Cardiology

Volumn 34, Issue 6, 2011, Pages 372-377

  Nakamura, Tsukasa ^a   Sato, Eiichi ^a   Fujiwara, Nobuharu ^a   Kawagoe, Yasuhiro ^a   Koide, Hikaru ^b   Ueda, Yoshihiko ^c   Takeuchi, Masayoshi ^d   Yamagishi, Sho Ichi ^e  

^a Shinmatsudo Central General Hospital   (Japan)

^b KOTO HOSPITAL   (Japan)

^c DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HOKURIKU UNIVERSITY   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; FATTY ACID BINDING PROTEIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; PROTEINURIA; RENAL PROTECTION;

ADULT; AMLODIPINE; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AZETIDINECARBOXYLIC ACID; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; DIHYDROPYRIDINES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; JAPAN; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, IMMUNOLOGIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958297167     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20885     Document Type: Article

References (33)

1. Yamagishi S, Imaizumi T., Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005; 11: 2279-2299. (Pubitemid 40872698)
2. Bucala R, Cerami A., Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol. 1992; 23: 1-34.
3. Rahbar S, Figarola JL., Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys. 2003; 419: 63-79. (Pubitemid 37287559)
4. Tahara N, Imaizumi T, Takeuchi M, et al. Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men. Oxid Med Cell Longev. 2010; 3: 262-265.
5. Nakamura T, Sato E, Fujiwara N, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism. 2009; 58: 1624-1628.
6. Yamagishi S, Matsui T., Advanced glycation end products (AGEs), oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010; 3: 101-108.
7. Bohlender JM, Franke S, Stein G, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol. 2005; 289: F645-F659. (Pubitemid 41324185)
8. Raj DS, Choudhury D, Welbourne TC, et al. Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis. 2000; 35: 365-380.
9. Yamagishi S, Matsui T, Nakamura K., Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets. 2007; 8: 1138-1143. (Pubitemid 47578142)
10. Nakamura K, Yamagishi S, Adachi H, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev. 2007; 23: 368-371. (Pubitemid 47091239)
11. Tan KC, Shiu SW, Chow WS, et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia. 2006; 49: 2756-2762.
12. Nakamura K, Yamagishi S, Matsui T, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med. 2007; 7: 188-190.
13. Humpert PM, Djuric Z, Kopf S, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol. 2007; 6: 9.
14. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications. 2003; 17: 16-21. (Pubitemid 36042787)
15. Nakamura K, Yamagishi S, Adachi H, et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev. 2008; 24: 109-114. (Pubitemid 351284754)
16. Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006; 55: 1227-1231. (Pubitemid 44215942)
17. Tanaka N, Yonekura H, Yamagishi S, et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000; 275: 25781-25790.
18. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008; 22: 3716-3727.
19. Yamagishi S, Inagaki Y, Nakamura K, et al. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharm. 2004; 43: 724-730. (Pubitemid 38534074)
20. Matsui T, Yamagishi S, Nakamura K, et al. Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells. J Int Med Res. 2006; 34: 671-675. (Pubitemid 46165392)
21. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007; 333: 321-326. (Pubitemid 46945471)
22. Yamagishi S, Takeuchi M, Inoue H., Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonists in advanced glycation end product (AGE)-injected rats. Int J Tissue React. 2005; 27: 137-143. (Pubitemid 41723730)
23. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (2 suppl 1): S1-S266.
24. Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007; 11: 41-50. (Pubitemid 46474965)
25. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharm Res. 2009; 60: 525-528.
26. Nakamura T, Sato E, Fujiwara N, et al. Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev. 2010; 3: 304-307.
27. Yamagishi S, Matsui T, Nakamura K., Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007; 7: 463-469. (Pubitemid 47244891)
28. Matsui T, Yamagishi S, Nakamura K, et al. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res. 2005; 31: 215-219. (Pubitemid 43052035)
29. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes. 2008; 57: 460-469.
30. Matsui T, Yamagishi S, Ueda S, et al. Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitro. Protein Pep Lett. 2010; 17: 74-77.
31. D'Amico G, Bazzi C., Pathophysiology of proteinuria. Kidney Int. 2003; 63: 809-825. (Pubitemid 36315559)
32. Burton C, Harris KP., The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis. 1996; 27: 765-775. (Pubitemid 26169027)
33. Ziyadeh FN, Goldfarb S., The renal tubulointerstitium in diabetes mellitus. Kidney Int. 1991; 39: 464-475.